[Pneumococcal vaccines. New conjugate vaccines for adults].

Autor:	Campins Martí M; Servicio de Medicina Preventiva y Epidemiología, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: mcampins@vhebron.net.
Jazyk:	Spanish; Castilian
Zdroj:	Enfermedades infecciosas y microbiologia clinica [Enferm Infecc Microbiol Clin] 2015 Nov; Vol. 33 (9), pp. 617-24. Date of Electronic Publication: 2015 Oct 23.
DOI:	10.1016/j.eimc.2015.09.002
Abstrakt:	Pneumococcal infections are a significant cause of morbidity and mortality, and are one of the 10 leading causes of death worldwide. Children under 2 years have a higher incidence rate, followed by adults over 64 years. The main risk group are individuals with immunodeficiency, and those with anatomical or functional asplenia, but can also affect immunocompetent persons with certain chronic diseases. Significant progress has been made in the last 10 years in the prevention of these infections. Until a few years ago, only the 23-valent non-conjugate pneumococcal vaccine was available. Its results were controversial in terms of efficacy and effectiveness, and with serious limitations on the type of immune response induced. The current possibility of using the 13-valent conjugate vaccine in adults has led to greater expectations in improving the prevention of pneumococcal disease in these age groups. (Copyright © 2015 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu